Moray Medical is a technology company.
Moray Medical has raised $6.0M across 1 funding round.
Moray Medical has raised $6.0M in total across 1 funding round.
Moray Medical has raised $6.0M in total across 1 funding round.
Moray Medical's investors include 415 CAPITAL.
Moray Medical is an interventional robotics startup developing the Coral system, a microfluidics-powered platform with an augmented reality digital user interface designed to simplify minimally invasive cardiovascular interventions, particularly transcatheter mitral valve repair.[1][2] It serves interventional cardiologists and patients with mitral regurgitation by addressing the complexity and steep learning curve of existing devices, enabling precise, cost-efficient procedures for a broader patient population that currently goes untreated.[1][5] The company raised $3.3 million in seed funding in 2021, signaling early growth momentum in the structural heart space.[1]
Founded around 2020-2021, Moray Medical emerged from the need to democratize advanced cardiovascular procedures amid the rise of transcatheter edge-to-edge repair (TEER or "clip therapy") as a standard of care.[1] Mark Barrish, an experienced medtech executive, serves as CEO and cofounder, driving the vision to empower interventionalists of all skill levels with intuitive robotics.[1] The seed round in January 2021, led by 415 Capital, marked a pivotal moment, with Azin Parhizgar, PhD (Chairwoman of CVPath Institute and 415 Capital's Senior Venture Partner) joining the board, validating the technology's potential for precision in complex 3D structural heart interventions.[1]
Moray Medical rides the wave of interventional robotics in structural heart disease, where transcatheter therapies like mitral valve repair are shifting from open surgery to minimally invasive standards amid aging populations and rising cardiovascular burdens.[1][2][3] Timing aligns with post-2021 growth in robotics adoption, fueled by AR/VR interfaces and microfluidics for sub-millimeter precision in cath labs. Market forces like device complexity limiting patient access (despite TEER's efficacy) favor Moray's simplifying platform, influencing the ecosystem by accelerating robotics in cardiology—potentially enabling telesurgery and broader global adoption.[1]
Moray Medical is poised to scale the Coral system toward clinical trials and FDA pathways, leveraging its seed momentum for partnerships with cath lab leaders amid surging demand for accessible TEER.[1] Trends like AI-augmented robotics and remote interventions will amplify its edge, potentially expanding to other vascular procedures. Its influence could evolve from niche innovator to ecosystem shaper, unlocking treatments for millions—echoing its founding mission to ensure no patient is left behind due to procedural barriers.[1]
Moray Medical has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $6.0M Seed | 415 CAPITAL |